glp-1 and eye disease Doctor Explains GLP 1 Blindness Risk (Should You Be Worried?) GLP-1 Receptor Agonists Could Reduce

Enter your state, county and plan name to start

Chhaya Makhija, MD, DipABLM Board-Certified Endocrinologist | Lifestyle Medicine Physician | Founder, Unified Endocrine & Diabetes Care Lafayette Fresno California Telemedicine (including Silicon Valley, Palo Alto, Menlo Park, San Francisco, Walnut Creek, Oakland, Sacramento) Watch or Listen to the Full Episode For a deeper dive into the science and real-world clinical nuance:

Additionally, researchers use preclinical models to examine how the metabolic effects of dual gastric inhibitory polypeptide (GIP)/GLP-1R agonists such as tirzepatide mediate anti-inflammatory and anti-fibrotic benefits, such as in metabolic dysfunction-associated steatotic liver disease

For many researchers, the net cardiovascular effect may actually be favorable despite the higher heart rate, because blood pressure reduction and weight loss both independently reduce cardiovascular risk